|
Synonyms: MABp1 | RA-18C3 | Xilonix® (proposed trade name)
Compound class:
Antibody
Comment: Bermekimab (MABp1, Xilonix) is an investigational fully human monoclonal antibody targeting IL-1α, with potential antiinflammatory action. This antibody is the first genuinely human monoclonal antibody to be produced directly from an affinity matured, human immune response. As MABp1 has not been subject to in vitro sequence modification it is predicted to have improved tolerability compared to antibodies that are 'humanised'.
A patent search suggests that Xilonix is the subject of WO2009148575 [3]. |
| Bioactivity Comments |
| MABp1's mechanism of action is predicted to be effective across a wide range of cancer types.The MABp1/IL-1α interaction as the primary mmoa is supported in the published literature [1-2]. The KD value in the table below is extracted from [3]. |
| Selectivity at ligand targets | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
